# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k120202   
B. Purpose for Submission: New device   
C. Measurand: Total Cholesterol   
D. Type of Test: Quantitative, Enzymatic Esterase – Oxidase Cholesterol   
E. Applicant: Vital Diagnostics (Manufacturing) Pty Ltd   
F. Proprietary and Established Names: Eon Cholesterol Reagent   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CHH</td><td rowspan=1 colspan=1>Class I, (meets limitationsof exemption per 21 CFR862.9(c)(4))</td><td rowspan=1 colspan=1>862.1175</td><td rowspan=1 colspan=1>Clinical Chemistry</td></tr></table>

# H. Intended Use:

1. Intended use(s): Refer to indications for use below

2. Indication(s) for use: Eon Cholesterol Reagent is an in vitro diagnostic device intended for the quantitative determination of total cholesterol in human plasma and serum using the Eon 100 Clinical Chemistry Analyzer. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.

3. Special conditions for use statement(s): For in vitro diagnostic use For prescription use

3. Special instrument requirements: Eon 100 Clinical Chemistry Analyzer (previously cleared in k100060)

# I. Device Description:

The Eon Cholesterol Reagent kit includes $4 \times 2 3 ~ \mathrm { m L }$ bottles that contain the following:

· 0.25 mmol/L 4-aminoantipyrine · 10.0 mmol/L Hydroxybenzoic acid (HBA) · $2 0 0 \mathrm { U / L }$ cholesterol oxidase (microbial) · ${ 5 0 0 } \mathrm { U } / \mathrm { L }$ cholesterol esterase (microbial) · $6 0 0 \mathrm { U } / \mathrm { L }$ peroxidase (horseradish)

As well as, buffer, surfactants, and other ingredients including sodium azide

Handle and dispose of all human source materials as though capable of transmitting infectious agents using the universal precautions recommended by the Centers for Disease Control and Prevention (CDC).

# J. Substantial Equivalence Information:

1. Predicate device name(s): Roche Cholesterol (CHOL) Reagent

2. Predicate 510(k) number(s): k952127

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Eon Cholesterol Reagent(Candidate Device)</td><td rowspan=1 colspan=1>Roche Cholesterol (CHOL)Reagent (Predicate -k952127)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Cholesterol Reagent isan in vitro diagnostic deviceintended for the quantitativedetermination of totalcholesterol in human plasmaand serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Cholesterol measurementsare used in the diagnosisand treatment of disordersinvolving excess cholesterolin the blood and lipid andlipoprotein metabolismdisorders.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Enzymatic (esterase/oxidaseend-point)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Patient Sample Type</td><td rowspan=1 colspan=1>Serum and Plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>6 - 775 mg/dL</td><td rowspan=1 colspan=1>3 - 800 mg/dL</td></tr><tr><td rowspan=1 colspan=1>On-board stability</td><td rowspan=1 colspan=1>28 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Limit of Detection</td><td rowspan=1 colspan=1>2 mg/dL</td><td rowspan=1 colspan=1>3 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Reagent configuration</td><td rowspan=1 colspan=1>Single part liquid</td><td rowspan=1 colspan=1>Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline

CLSI EP05-A2: Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline – Second Edition

CLSI EP09-A2-IR: Method Comparison and Bias Estimation using Patient Samples; Approved Guideline – Second Edition (Interim Revision)

CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline

# L. Test Principle:

Free cholesterol and cholesterol produced from the enzymatic hydrolysis of cholesterol esters are oxidized in the presence of cholesterol oxidase. The resulting hydrogen peroxide reacts with Hydroxybenzoic acid (HBA) and 4-aminoantipyrine to produce a red quinoneimine dye in the presence of peroxidase. The red quinoneimine dye absorbs at $5 0 5 \mathrm { n m }$ . The final

absorbance at this wavelength is proportional to the concentration of total cholesterol in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Four levels of control serum were tested on the Eon 100 analyzer two times per run, two runs per day for 20 days $( \mathrm { n } = 8 0 $ ). The results are summarized in the tables below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 120.6 mg/dLCholesterol</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation, %</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2Mean 185.6 mg/dLCholesterol</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation, %</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.8</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3Mean 249.2 mg/dLCholesterol</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation, %</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.5</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 413.2 mg/dLCholesterol</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>6.2</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation, %</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.5</td></tr></table>

# b. Linearity/assay reportable range:

Linearity studies were carried out using serial dilutions of a commercially available serum cholesterol concentrate. The range tested was $5 . 0 - 8 3 2 . 0 \mathrm { m g / d L }$ . A polynomial fit analysis did not indicate statistically significant non linearity. The linear regression analysis is provided below:

<table><tr><td rowspan=1 colspan=1>Claimed MeasuringRange</td><td rowspan=1 colspan=1>Intercept (95%CI)(mg/dL)</td><td rowspan=1 colspan=1>Slope (95% CI)</td></tr><tr><td rowspan=1 colspan=1>6 - 775 mg/dL</td><td rowspan=1 colspan=1>-0.7 (-5.4-4.0)</td><td rowspan=1 colspan=1>0.996 (0.989 - 1.006)</td></tr></table>

Based on the linearity data, the measuring range claim $6 - 7 7 5 \mathrm { m g / d L }$ is supported.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Reagent Traceability

A Cholesterol Reference Method Laboratory Network (CRMLN) Certificate of Traceability for the Eon Cholesterol Reagent was provided.

Reagent Stability

Closed vial/Shelf life

Accelerated heat stress stability studies have concluded that the reagent is stable for 21 months when stored at $2 - 8 \ ^ { \circ } \mathrm { C }$ . Initial shelf-life claims will be for 18 months; however, real-time studies are on-going and the final claim will be reflected by realtime results. Closed vial/Shelf life protocols and acceptance criteria were reviewed and found to be acceptable.

Open vial/On-board Stability

Open vial/On-board stability protocols and acceptance criteria were reviewed and found to be acceptable. The Eon Cholesterol Reagent demonstrated on-board stability of 28 days.

Eon calibrators, as referenced in the package insert, were cleared in k110394 under the name ATAC Serum Calibrator (Direct Bilirubin and Iron)

Eon controls, as referenced in the package insert, were cleared in k111063 under the name Vital Serum Controls

# d. Detection limit:

Protocols for the determination of the limit of blank (LoB) and the limit of detection (LoD) were performed in accordance with the recommendations in the CLSI Guideline EP17-A. Testing was carried out using true blanks and low level samples (total 60 each) on two Eon 100 analyzers. The calculated LoB of $0 . 7 0 ~ \mathrm { m g / d L }$ and LoD of $1 . 5 \mathrm { m g / d L }$ support a LoB and LoD claim of 1 and $2 \mathrm { m g / d L }$ , respectively. The measuring range of the assay is 6 to $7 7 5 \mathrm { m g / d L }$ .

# e. Analytical specificity:

Interference studies were performed by using serum pools containing cholesterol (2 levels) with individual interferents at a range of concentrations. The sera were assayed for cholesterol $\ln \geq 3$ replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery exceeded $\pm$ $10 \%$ . The results were obtained on the Eon 100 analyzer.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Level 1</td><td rowspan=1 colspan=2>Level 2</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>CholesterolConc.(mg/dL)</td><td rowspan=1 colspan=1>Nointerferenceat this levelofinterferent(mg/dL)</td><td rowspan=1 colspan=1>CholesterolConc.(mg/dL)</td><td rowspan=1 colspan=1>Nointerferenceat this levelofinterferent(mg/dL)</td><td rowspan=1 colspan=1>InterferenceClaim(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>230</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Nointerferenceup to 500</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Nointerferenceup to 1000</td></tr><tr><td rowspan=1 colspan=1>Bilirubin,conjugated</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>Nointerferenceup to 7.5</td></tr><tr><td rowspan=1 colspan=1>Bilirubin,unconjugated</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>Nointerferenceup to 7.5</td></tr><tr><td rowspan=1 colspan=1>Ascorbicacid</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>229</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Nointerferenceup to 5</td></tr><tr><td rowspan=1 colspan=1>Gentisic acid</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>117(μmol/L)</td><td rowspan=1 colspan=1>254</td><td rowspan=1 colspan=1>117(μmol/L)</td><td rowspan=1 colspan=1>Nointerferenceup to 117(μmol/L)</td></tr><tr><td rowspan=1 colspan=1>Dopamine</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>5.9(μmol/L)</td><td rowspan=1 colspan=1>251</td><td rowspan=1 colspan=1>5.9(μmol/L)</td><td rowspan=1 colspan=1>Nointerferenceup to 5.9(μmol/L)</td></tr></table>

f. Assay cut-off:

· Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

Studies were carried out according to CLSI EP09-A2-IR. Serum samples $( \mathrm { n } { = } 1 0 1$ ) were assayed in parallel by both the test (Y) and predicate (X) methods. The results were analyzed by using both Least squares and Deming regression. The range tested $1 0 - 7 5 0 \mathrm { m g / d L }$ . Altered samples were included in the study.

<table><tr><td rowspan=1 colspan=1>LinearRegression</td><td rowspan=1 colspan=1>Range(Predicate)</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>Standarderror est.</td></tr><tr><td rowspan=1 colspan=1>Leastsquares</td><td rowspan=2 colspan=1>10-750(mg/dL)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.995(0.979-1.011)</td><td rowspan=1 colspan=1>3.422(-0.630 - 7.474)</td><td rowspan=1 colspan=1>0.9968</td><td rowspan=1 colspan=1>10.294</td></tr><tr><td rowspan=1 colspan=1>Deming</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.998(0.982 - 1.012)</td><td rowspan=1 colspan=1>2.722(-1.33 - 6.777)</td><td rowspan=1 colspan=1>0.9968</td><td rowspan=1 colspan=1>10.303</td></tr></table>

$b$ . Matrix comparison:

Parallel drawn (matched) samples from 68 individuals were collected as serum and anti-coagulated plasma (Lithium heparin. The paired samples for each individual were assayed in parallel with Eon cholesterol reagent on the Eon 100 analyzer. The results were analyzed by using both Least squares and Deming regression. The range tested $1 4 - 6 8 0 \mathrm { m g / d L }$ . Altered samples were included in the study.

<table><tr><td rowspan=1 colspan=1>LinearRegression</td><td rowspan=1 colspan=1>Range(serum)</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>Standarderror est.</td></tr><tr><td rowspan=1 colspan=1>Leastsquares</td><td rowspan=2 colspan=1>14 - 680(mg/dL)</td><td rowspan=2 colspan=1>68</td><td rowspan=1 colspan=1>0.965(0.943 - 0.987)</td><td rowspan=1 colspan=1>5.389(0.362  10.416)</td><td rowspan=1 colspan=1>0.9956</td><td rowspan=1 colspan=1>9.926</td></tr><tr><td rowspan=1 colspan=1>Deming</td><td rowspan=1 colspan=1>0.969(0.947  0.992)</td><td rowspan=1 colspan=1>4.576(-0.456 - 9.608)</td><td rowspan=1 colspan=1>0.9956</td><td rowspan=1 colspan=1>9.936</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: · Not applicable

b. Clinical specificity: · Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): · Not applicable

4. Clinical cut-off: · Not applicable

5. Expected values/Reference range:

For cholesterol, the National Cholesterol Education Program (NCEP) recommends classifying patient results as being desirable, borderline or high based on the following cut-off thresholds established by the Adult Treatment Panel (ATP) III:

Desirable: $< 2 0 0 ~ \mathrm { m g / d L }$ Borderline: $2 0 0 - 2 3 9 \mathrm { m g / d L }$ $\mathrm { H i g h } { : } \geq 2 4 0 ~ \mathrm { m g / d L }$

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.